Johnson & Johnson Innovation (Boston) and Janssen Biotech, Inc. have announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline.

Utilizing the Belfer Institute's proprietary immuno-oncology lung platform and lung cancer disease expertise, the research teams will also seek to identify rational immuno-oncology drug combination strategies and biomarkers and to characterize mechanisms of resistance. The collaboration will also identify and validate novel targets for lung cancers.

Source: Johnson & Johnson